Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMVT vs MLTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMVT Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

IMVT Overall Winner 6-Pillar Tally: IMVT 2 – 2 MLTX (2 Tie) Matrix Metrics: IMVT 4 – 1 MLTX

As of Nov 16, 2026, Immunovant, Inc. (IMVT) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). IMVT carries a Unified Composite Score of 39.6/100 (SELL) at $33.30 (N/M Forward P/E, 0.0% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both IMVT (39.6/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: IMVT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMVT vs MLTX
IMVT NASDAQ Head-to-Head Winner
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap $7.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 72% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $30.82 · SMA50: $32.52
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82

6-Pillar Scorecard Institutional Category Breakdown (IMVT 2 – 2 MLTX)

Columns: Metric · IMVT · MLTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale IMVT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $7.3B $1.1B
3. Profitability & Quality MLTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -86.5% -81.5%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$395M -$244M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.18 Book/Sh · -86.5% ROE $278M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMVT
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 54.1% (6th %ile) 111.8% (7th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMVT (4) vs MLTX (1)
Institutional Metric IMVT MLTX Criterion Row Edge
Market Capitalization
Scale
$7.3B $1.1B Larger Scale IMVT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-86.5% -81.5% Higher ROE MLTX
52-Week Range Position
Momentum
49% ($22–$45) 17% ($9–$23) Stronger Trend IMVT
Beta / 30D Volatility
Risk Regime
1.74β · 72% Vol 1.61β · 90% Vol Lower Realized Risk IMVT
Unified Institutional Score
Composite Signal
39.6 / 100 (SELL) 38.3 / 100 (SELL) Higher Composite IMVT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$395M ($3.18 Book/Sh · -86.5% ROE) -$244M ($278M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMVT +0.52 pp
IMVT: +24.6% · MLTX: +24.08%
3M Horizon IMVT +2.66 pp
IMVT: -24.82% · MLTX: -27.48%
6M Horizon IMVT +53.46 pp
IMVT: +25.54% · MLTX: -27.92%
1Y Horizon IMVT +51.6 pp
IMVT: +45.95% · MLTX: -5.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMVT vs MLTX. Trailing 12-month operating profitability (IMVT 0.0% vs MLTX 0.0%) and valuation multiples (IMVT N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMVT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-86.5% · N/M
MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMVT CONSOLIDATION
93d in phase · OBV ACCUMULATION
Current IV 54.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMVT vs MLTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immunovant, Inc. (IMVT) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). IMVT carries a Unified Composite Score of 39.6/100 (SELL) at $33.30 (N/M Forward P/E, 0.0% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both IMVT (39.6/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IMVT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.5); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMVT leads the Growth & Scale pillar: IMVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMVT generates N/A in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, IMVT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.

IMVT and MLTX trade at balanced relative valuation multiples. IMVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMVT (-86.5% ROE) versus MLTX (-81.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IMVT carries 54.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 72% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.